Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Acacia Pharma Group plc: TR-1: Standard form for notification of major holdings

Acacia Pharma Group plc
Posted on: 09 Mar 18

TR-1: S tandard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Acacia Pharma Group plc.
1b. Please indicate if the issuer is a non-UK issuer   (please mark with an "X" if appropriate)
Non-UK issuerx
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rightsx
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rights 
Other (please specify) iii :  
3. Details of person subject to the notification obligation iv
NameThe Novo Nordisk Foundation
City and country of registered office (if applicable)Tuborg Havnevej 19, 2900 Hellerup, Denmark
4. Full name of shareholder(s) (if different from 3.) v
NameNovo Holdings A/S
City and country of registered office (if applicable)Tuborg Havnevej 19, 2900 Hellerup, Denmark
5. Date on which the threshold was crossed or reached vi : 06/03/2018
6. Date on which issuer notified (DD/MM/YYYY): 08/03/2018
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuer vii
Resulting situation on the date on which threshold was crossed or reached14.4% 14.4%7,609,551
Position of previous notification (if
applicable)
    


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)
Number of voting rights ix % of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary Shares
GB00BYWF9Y76
7,609,551 7,609,551 
     
     
SUBTOTAL 8. A 7,609,5517,609,551
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration
date x
Exercise/
Conversion Period xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
     
     
     
   SUBTOTAL 8. B 1   
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration
date x
Exercise/
Conversion Period xi
Physical or cash
settlement xii
Number of voting rights % of voting rights
      
      
      
     SUBTOTAL 8.B.2   
 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii  
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary)
x
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
The Novo Nordisk Foundation14.4% 14.4%
Novo Holdings A/S14.4% 14.4%
    
    
    
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional information xvi
 

The shares are held by Novo Holdings A/S, the holding company in the Novo Group. Novo Holdings A/S is wholly-owned by the Novo Nordisk Foundation.

Place of completion Hellerup, Denmark
Date of completion 08.03.2018


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Acacia Pharma Group plc via GlobeNewswire
HUG#2175198
GlobeNewswire
globenewswire.com

Last updated on: 10/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.